Info

CytRx Corporation (CytRx) is a clinical-stage biopharmaceutical company engaged in developing human therapeutic products based primarily upon its small-molecule molecular chaperone amplification technology. As of December 31, 2007, the Company is using its chaperone amplification technology to develop treatments for neurodegenerative disorders and diabetic complications. In December 2007, it began enrolling patients in its Phase IIb efficacy clinical trial of the Company’s product candidate, arimoclomol, for amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease. Iroxanadine, its second small-molecule product candidate, completed Phase I clinical trials. The results from the Phase I trials indicated that orally-administered iroxanadine was safe and well tolerated in healthy volunteers. The Company also owns several other small-molecule compounds that amplify molecular chaperone proteins in human cells. In September 2008, CytRx acquired Innovive Pharmaceuticals, Inc.